Shanghai Allist Pharmaceuticals Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai Allist Pharmaceuticals Co., Ltd.

Why is Shanghai Allist Pharmaceuticals Co., Ltd. ?

The company has declared Positive results for the last 10 consecutive quarters

OPERATING CASH FLOW(Y) Highest at CNY 2,163.79 MM
NET PROFIT(HY) At CNY 1,187.76 MM has Grown at 59.72%
ROCE(HY) Highest at 34.9%

With ROE of 29.16%, it has a attractive valuation with a 7.88 Price to Book Value

Over the past year, while the stock has generated a return of 14.68%, its profits have risen by 65.8%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Shanghai Allist Pharmaceuticals Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shanghai Allist Pharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Shanghai Allist Pharmaceuticals Co., Ltd.

12.99%

1.20

37.77%

China Shanghai Composite

26.42%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

443.87%

EBIT Growth (5y)

50.71%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.65

Sales to Capital Employed (avg)

0.60

Tax Ratio

13.82%

Dividend Payout Ratio

20.46%

Pledged Shares

Institutional Holding

ROCE (avg)

27.87%

ROE (avg)

10.46%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.88

EV to EBIT

23.97

EV to EBITDA

23.45

EV to Capital Employed

20.71

EV to Sales

10.31

PEG Ratio

Dividend Yield

ROCE (Latest)

86.39%

ROE (Latest)

29.16%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 2,163.79 MM

NET PROFIT(HY)

At CNY 1,187.76 MM has Grown at 59.72%

ROCE(HY)

Highest at 34.9%

DEBTORS TURNOVER RATIO(HY)

Highest at 13.75 times

NET SALES(Q)

Highest at CNY 1,359.26 MM

RAW MATERIAL COST(Y)

Fallen by -1.59% (YoY

CASH AND EQV(HY)

Highest at CNY 7,271.52 MM

OPERATING PROFIT(Q)

Highest at CNY 618.59 MM

-11What is not working for the Company

INTEREST(HY)

At CNY 0.08 MM has Grown at 170.9%

DEBT-EQUITY RATIO (HY)

Highest at -50.39 %

Here's what is working for Shanghai Allist Pharmaceuticals Co., Ltd.

Operating Cash Flow

Highest at CNY 2,163.79 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

Highest at CNY 1,359.26 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (CNY MM)

Net Profit

At CNY 1,187.76 MM has Grown at 59.72%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Debtors Turnover Ratio

Highest at 13.75 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales

At CNY 1,359.26 MM has Grown at 24.84%

over average net sales of the previous four periods of CNY 1,088.8 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Operating Profit

Highest at CNY 618.59 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Cash and Eqv

Highest at CNY 7,271.52 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -1.59% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Allist Pharmaceuticals Co., Ltd.

Interest

At CNY 0.08 MM has Grown at 170.9%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -50.39 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio